The Journal of
Clinical Psychiatry

Schizophrenia/Schizoaffective Disorders

ASCP Corner May 11, 2008

Antipsychotic Polypharmacy, Part 2: Why Use 2 Antipsychotics When 1 Is Not Good Enough?

Christoph U. Correll, MD

J Clin Psychiatry 2008;69(5):860-861

Article Abstract

Last month’s CORNER article examinedthe potential reasons and rationales for andconcerns about the combined use of antipsychotics.This article will review theevidence regarding the efficacy and safetyof antipsychotic polypharmacy in the treatmentof schizophrenia.

Download Free PDF

Enjoy free PDF downloads as part of your membership!

Save Save

Cite

Advertisement
GAM ID: sidebar-top

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Advertisement
GAM ID: sidebar-bottom

Vol 85 • 2024 • Number 3

Read the Current Issue

Editorial

Focus on Women’s Mental Health: Twenty Years and Counting

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Commentary

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Original Research

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Original Research

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Original Research

Aripiprazole Lauroxil Initiation Regimens

View current Issue

Related Articles

SSRI Behavioral Activation, the Boxed Bolded Warning, and Neurodevelopmental Disorders

ASCP Corner

SSRI Behavioral Activation, the Boxed Bolded Warning, and Neurodevelopmental Disorders

April 2, 2024

Mayank Gupta, MD, discusses SSRI use and the risk of behavioral activation and suicidality in people with autism spectrum disorders.

Mayank Gupta

Where Does Lamotrigine Fit in the Pharmacotherapy of Mood Disorders?

ASCP Corner

Where Does Lamotrigine Fit in the Pharmacotherapy of Mood Disorders?

January 31, 2024

This article provides a practical overview of the evidence supporting lamotrigine’s efficacy and identifies shortcomings of previous study designs.

Joseph F. Goldberg

When and How to Use Lithium Augmentation for MDD

ASCP Corner

When and How to Use Lithium Augmentation for MDD

March 8, 2023

With its antisuicidal effect and low cost, lithium can be an effective alternative to other MDD augmentation strategies when antidepressants are not enough.

Mete Ercis, Aysegul Ozerdem, Balwinder Singh